139 related articles for article (PubMed ID: 38830504)
1. Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.
Callenbach MHE; Goettsch WG; Mantel-Teeuwisse AK; Trusheim M
Drug Discov Today; 2024 Jun; 29(7):104048. PubMed ID: 38830504
[TBL] [Abstract][Full Text] [Related]
2. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.
Vreman RA; Broekhoff TF; Leufkens HG; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33182732
[TBL] [Abstract][Full Text] [Related]
3. Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®).
Callenbach MHE; Schoenmakers D; Vreman RA; Vijgen S; Timmers L; Hollak CEM; Mantel-Teeuwisse AK; Goettsch WG
Value Health; 2024 May; ():. PubMed ID: 38795960
[TBL] [Abstract][Full Text] [Related]
4. When Reality Does Not Meet Expectations-Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs.
Callenbach MHE; Vreman RA; Mantel-Teeuwisse AK; Goettsch WG
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612665
[TBL] [Abstract][Full Text] [Related]
5. Critical Reflections on Reimbursement and Access of Advanced Therapies.
Simoens S; De Groote K; Boersma C
Front Pharmacol; 2022; 13():771966. PubMed ID: 35662719
[No Abstract] [Full Text] [Related]
6. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
7. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
8. Outcome-based reimbursement in Central-Eastern Europe and Middle-East.
Ádám I; Callenbach M; Németh B; Vreman RA; Tollin C; Pontén J; Dawoud D; Elvidge J; Crabb N; van Waalwijk van Doorn-Khosrovani SB; Pisters-van Roy A; Vincziczki Á; Almomani E; Vajagic M; Oner ZG; Matni M; Fürst J; Kahveci R; Goettsch WG; Kaló Z
Front Med (Lausanne); 2022; 9():940886. PubMed ID: 36213666
[TBL] [Abstract][Full Text] [Related]
9. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
10. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
11. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
12. Accelerating patient access to oncology medicines with multiple indications in Europe.
Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
[No Abstract] [Full Text] [Related]
13. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
14. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
Facey KM; Espin J; Kent E; Link A; Nicod E; O'Leary A; Xoxi E; van de Vijver I; Zaremba A; Benisheva T; Vagoras A; Upadhyaya S
Pharmacoeconomics; 2021 Sep; 39(9):1021-1044. PubMed ID: 34231135
[TBL] [Abstract][Full Text] [Related]
15. Facilitating [corrected] More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework.
Whittal A; Jommi C; De Pouvourville G; Taylor D; Annemans L; Schoonaert L; Vermeersch S; Hutchings A; Patris J
Int J Technol Assess Health Care; 2022 Mar; 38(1):e23. PubMed ID: 35274602
[TBL] [Abstract][Full Text] [Related]
16. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
17. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
18. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
Sekayan T; Simmons DH; von Drygalski A
Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
[TBL] [Abstract][Full Text] [Related]
19. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
Michelsen S; Nachi S; Van Dyck W; Simoens S; Huys I
Front Pharmacol; 2020; 11():594446. PubMed ID: 33363468
[No Abstract] [Full Text] [Related]
20. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2017; 5(1):1355203. PubMed ID: 28839525
[No Abstract] [Full Text] [Related]
[Next] [New Search]
